RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta +19 more·2015·Nature Communications

DOI 10.1038/ncomms7377

Cited by (655)

Items 201–300 of 655

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Talal El Zarif, Catherine Belle Meador, Xintao Qiu, Ji-Heui Seo, Matthew P. Davidsohn, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M. McClure, John Canniff, Brad J. Fortunato et al. · 2024 · Clinical Cancer Research
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
Hatim Husain, Michael D. Scur, Ayesha Murtuza, Nam Q. Bui, Brian D. Woodward, Razelle Kurzrock · 2017 · Molecular Cancer Therapeutics
Recent advances in the molecular landscape of lung neuroendocrine tumors
Giuseppe Pelosi, Fabrizio Bianchi, Paul M Hofman, Linda Pattini, Philipp Ströbel, Fiorella Calabrese, Salma Naheed, Chloe Holden, Judith Cave, Hanibal Bohnenberger et al. · 2019 · Expert Review of Molecular Diagnostics
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
Alessandro Leonetti, Roberta Minari, Giulia Mazzaschi, Letizia Gnetti, Silvia La Monica, Roberta R Alfieri, Nicoletta Campanini, Michela Verzè, Andrea Olivani, Luigi Ventura et al. · 2021 · Frontiers in Oncology
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Bin-Chi Liao, Sebastian Griesing, James Chih‐Hsin Yang · 2019 · Therapeutic Advances in Medical Oncology
GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer
Lifang Cheng, Lan-ying Gou, Ting Wei, Jian Zhang · 2020 · International Journal of Oncology
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Sohini Roy, Tarsheen Kaur Sethi, David Taylor, Young Jin Kim, Douglas Buckner Johnson · 2020 · Journal of Leukocyte Biology
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics
Ming Tang, Hussein A. Abbas, Marcelo Vailati Negrao, Maheshwari Ramineni, Xin Hu, Shawna Marie Hubert, Junya Fujimoto, Alexandre Reuben, Susan Varghese, Jianhua Zhang et al. · 2021 · Nature Communications
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures
Maise Al Bakir, James L. Reading, Samuel Gamble, Rachel Rosenthal, Imran Uddin, Andrew Rowan, Joanna Przewrocka, Amber Rogers, Yien Ning Sophia Wong, Amalie Kai Bentzen et al. · 2025 · Nature
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression
Mark A. Socinski, Liza Cosca Villaruz, Jeffrey S. Ross · 2016 · The Oncologist
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
Federico Cappuzzo, Alessandro Morabito, Nicola Normanno, Paolo Bidoli, Alessandro Del Conte, Laura Giuseppina Giannetta, Agnese Montanino, Francesca Mazzoni, Roberta Buosi, Marco Angelo Burgio et al. · 2016 · Lung Cancer
Circulating tumor DNA testing in advanced non-small cell lung cancer
Everett James Moding, Maximilian Diehn, Heather A. Wakelee · 2018 · Lung Cancer
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
Tongji Xie, Yan Li, Jianming Ying, Weijing Cai, Junling Li, Kye Young Lee, Biagio Ricciuti, Jose M. Pacheco, Puyuan Xing · 2020 · Translational Lung Cancer Research
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Camille Léonce, Pierre Saintigny, Sandra Ortiz‐Cuaran · 2021 · Molecular Cancer Research
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer
Kenichi Suda, Isao Murakami, Kazuko Sakai, Kenji Tomizawa, Hiroshi Mizuuchi, Katsuaki Sato, Kazuto Nishio, Tetsuya Mitsudomi · 2015 · Lung Cancer
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression
Hiroshi Kotani, Hiromichi Ebi, Hidenori Kitai, Shigeki Nanjo, Kenji Kita, Tiffany G. Huynh, A Ooi, Anthony C. Faber, Mari A. Mino-Kenudson, Seiji Yano · 2015 · Oncogene
Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer
Yusuke Inoue, Ana Nikolić, Dylan Farnsworth, Rocky Shi, Fraser D. Johnson, Alvin Liu, Marc Ladanyi, Romel Somwar, Marco Gallo, William Wirt Lockwood · 2021 · eLife
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
Antonio Passaro, Tony S.K. Mok, Ilaria Attili, Yi-Long Lung Cancer Wu, Masahiro Tsuboi, Filippo de Marinis, Solange Peters · 2023 · JAMA Oncology
USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
Juntae Kwon, Jinmin Zhang, Boram Mok, Samuel Allsup, Chul Kim, Jeffrey A. Toretsky, Cecil Han · 2023 · Molecular Cancer
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Darin Poei, Sana Ali, Shirley Ye, Robert C. Hsu · 2024 · Cancer Drug Resistance
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
Felix Carl Saalfeld, Johanna Möller, Petros Christopoulos, Carina Wenzel, Anna Rasokat, Xuejun Alice Wang, Ioannis Athanasios Vathiotis, David König, Oliver Illini, Christian Grohé et al. · 2024 · European Journal of Cancer
Pathological transition as the arising mechanism for drug resistance in lung cancer
Yueqing Chen, Waiying Yvonne Tang, Xinyuan Tong, Hongbin Ji · 2019 · 癌症：英文版
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome
Qian Zhang, Elena J. Orlando, Hong Y. Wang, Agata M. Bogusz, Xiaobin Liu, Simon Francis Lacey, Honore T. Strauser, Selene Nuñez-Cruz, Reza Nejati, Paul J. Zhang et al. · 2020 · Blood
The genomic landscape of young and old lung cancer patients highlights age‐dependent mutation frequencies and clinical actionability in young patients
Lei Cai, Yong Chen, Xiaoling Tong, Xue Wu, Hua Bao, Yang Washington Shao, Zhuang Luo, Xuming Wang, Yang Cao · 2021 · International Journal of Cancer
Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
Yingjiao Xue, Shenda Hou, Hongbin Ji, Xiangkun Han · 2016 · Protein & Cell
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer
Ferdinandos Skoulidis, Vassiliki A. Papadimitrakopoulou · 2016 · Clinical Cancer Research
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Beatrice Gini, Nicholas J. Thomas, Collin Michael Blakely · 2020 · Journal of Thoracic Disease
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Daniel Sentana‐Lledo, Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Paul A. VanderLaan, Daniel Botelho Costa · 2023 · Translational Lung Cancer Research
Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy
Jiao Zeng, Xinjing Ding, Jianghua Ding, Xin Wang · 2023 · Frontiers in Immunology
ALK-Rearranged Adenocarcinoma Transformed to Small-Cell Lung Cancer: A New Entity with Specific Prognosis and Treatment?
Charbel S. Hobeika, Gaëlle Rached, Roland Eid, Fadi Haddad, Salim Chucri, Hampig Raphaël Kourié, Joseph Gergi Kattan · 2018 · Personalized Medicine
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors
Xiuning Le, Neelam Vijay Desai, Adnan Majid, Rebecca Karp Leaf, Mark S. Huberman, Deepa Rangachari, Michael Sean Kent, Sidhu P. Gangadharan, Erik E. Folch, Paul A. VanderLaan et al. · 2015 · Lung Cancer
Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence
Wang, Xiaojing, Min, Shengping, Liu, Hongli, Wu, Nan, Liu, Xincheng, Wang, Tao, Li, Wei, Shen, Yuanbing, Wang, Hongtao, Qian, Zhongqing et al. · 2019 · EMBO Molecular Medicine
Epithelial cell plasticity: breaking boundaries and changing landscapes
Aleksandra Tata, Ryan Dz-Wei Chow, Purushothama Rao Tata · 2021 · EMBO Reports
Small cell lung cancer transformations from non-small cell lung cancer: Biological mechanism and clinical relevance
Yang Yang, Songqing Fan · 2024 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
Keeping it together: Pulmonary alveoli are maintained by a hierarchy of cellular programs
Catriona Y. Logan, Tushar Desai · 2015 · BioEssays
TIPE1 function as a prognosis predictor and negative regulator of lung cancer
Xiao‐Cheng Wu, Yunmiao Ma, Cheng Ji, Xia Li, Hui Zheng, Li Jiang, Renjie Zhou · 2017 · Oncotarget
Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors
Harun Patel, Azim Ansari, Rahul H. Pawara, Iqrar Ansari, Harsha Jadhav, Sanjay Javerilal Surana · 2018 · Journal of Receptors and Signal Transduction
Neuroendocrine Tumors of the Lung
Yin Pun Hung · 2019 · Surgical pathology clinics
Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance
Harsimar B. Kaur, Iryna V. Samarska, Jiayun Lu, Farzana A. Faisal, Benjamin Louis Maughan, Sanjana Murali, Kaushal V. Asrani, Mohamed Alshalalfa, Emmanuel S. Antonarakis, Jonathan I. Epstein et al. · 2020 · The Prostate
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Alejandro Ríos-Hoyo, Laura Moliner, Edurne Arriola · 2022 · Cancers
RETRACTED ARTICLE: Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth
Li, Juan, Liu, Jie, Liang, Zheyong, He, Fang, Yang, Lu, Li, Pingping, Jiang, Yina, Wang, Bo, Zhou, Can, Wang, Yaochun et al. · 2017 · Cell Death & Disease · Retracted
Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer
Steven P. Angus, Jon S. Zawistowski, Gary L. Johnson · 2017 · The Annual Review of Pharmacology and Toxicology
Clusterin modulates transdifferentiation of non-small-cell lung cancer
Runsen Jin, Xingshi Chen, Dingpei Han, Xiaoying Luo, Hecheng Li · 2017 · BMC Cancer
Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
Ranjan Pathak, Victoria Meucci Villaflor · 2021 · Cancers
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Z. Liu, Lok-Hei Chan, Jungmin Choi, Mary Ann Melnick, Anna Arnal Estape, Zenta Walther, Dejian Zhao et al. · 2024 · Cancer Research
Lineage plasticity and histological transformation: tumor histology as a spectrum
Xiaoling Li, Eric E. Gardner, Sonia Molina‐Pinelo, Clare Wilhelm, Ping Mu, Àlvaro Quintanal-Villalonga · 2025 · Cell Research
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib
Koji Haratani, Hidetoshi Hayashi, Satomi Watanabe, Hiroyasu Kaneda, Takeshi Yoshida, Masayuki Takeda, Toshio Shimizu, Kazuhiko Nakagawa · 2015 · Annals of Oncology
Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
Fei Zhou, Likun Hou, Ting Ding, Quanming Song, Xiaoxia Chen, Chunxia Su, Wei Li, Guanghui Gao, Shengxiang Ren, Fengying Wu et al. · 2017 · Lung Cancer
Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo
Zhongwei Liu, Weimin Gao · 2019 · Archives of Toxicology
Tumor Milieu Controlled by RB Tumor Suppressor
Shunsuke Kitajima, Fengkai Li, Chiaki Takahashi · 2020 · International Journal of Molecular Sciences
Cellular Heterogeneity–Adjusted cLonal Methylation (CHALM) improves prediction of gene expression
Jianfeng Xu, Jiejun Shi, Xiaodong Cui, Ya Cui, Jingyi Jessica Li, Ajay Goel, Xi Chen, Jean‐Pierre J. Issa, Jianzhong Su, Wei Li · 2021 · Nature Communications
Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer
Sara Baglivo, Vienna Ludovini, Angelo Sidoni, Giulio Metro, Biagio Ricciuti, Annamaria Siggillino, Alberto Rebonato, Salvatore Gerardo Messina, Lucio Crinò, Rita Chiari · 2017 · Mayo Clinic Proceedings
Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas
Yan Li, Tongji Xie, Shouzheng Wang, Lin Yang, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Junling Li, Jianming Ying et al. · 2024 · Signal Transduction and Targeted Therapy
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti · 2020 · Translational Lung Cancer Research
Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression
Ioannis Sanidas, Hanjun Lee, Purva H. Rumde, Gaylor Boulay, Robert Tyler Morris, Gabriel Golczer, Marcello Stanzione, Soroush Hajizadeh, Jun Wen Zhong, Meagan B. Ryan et al. · 2022 · Molecular Cell
Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
Yoshimi Ohashi, Mutsumi Okamura, Ryohei Katayama, Siyang Fang, Saki Tsutsui, Akinobu Akatsuka, Mingde Shan, Hyeong-Wook Choi, Naoya Fujita, Kentaro Yoshimatsu et al. · 2017 · Oncotarget
Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors
Jay Gong, Jeffrey P. Gregg, Weijie Ma, Ken Y. Yoneda, Elizabeth Hernández Moore, Megan Eileen Daly, Yanhong Zhang, Melissa J. Williams, Tianhong Li · 2019 · Journal of the National Comprehensive Cancer Network
Unraveling cancer lineage drivers in squamous cell carcinomas
Yinglu Guan, Guan Wang, Danielle Fails, Priyadharsini Nagarajan, Yejing Ge · 2019 · Pharmacology & Therapeutics
Histologic transformation in lung cancer: when one door shuts, another opens
Yuki Sato, Go Saito, Daichi Fujimoto · 2022 · Therapeutic Advances in Medical Oncology
Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms
Aya Shiba‐Ishii, Noriko Takemura, Hitomi Kawai, Daisuke Matsubara · 2024 · Cancer Science
Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity
Avisek Banerjee, Ioannis Athanasios Vathiotis, Debdatta Halder, Utsav Sen, Xuejun Wang, Misty Dawn Shields, Rajwanth R. Veluswamy, Konstantinos Syrigos, Fred R. Hirsch, Triparna Sen · 2025 · Journal of Thoracic Oncology
Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling
Ugo Testa, Elvira Pelosi, Germana Castelli · 2021 · Expert Review of Molecular Diagnostics
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
Jill Kolesar, Keng Hee Peh, Levin Thomas, Gayathri Baburaj, Nayonika Mukherjee, Raveena Kantamneni, Shirley Christabel Lewis, Ananth Pai, Karthik Udupa, Naveena A. N. Kumar et al. · 2022 · Molecular Cancer
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia‐Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tinè, Giulia Pasello, Paul M Hofman · 2022 · International Journal of Molecular Sciences
Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis
Koichi Andō, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Hironori Sagara · 2023 · International Journal of Molecular Sciences
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
Qinfang Deng, Boxiong Xie, Leilei Wu, Xianxiu Ji, Chao Li, Feng Li, Qiyu Fang, Yuchen Bao, Jialu Li, Shengnan Jin et al. · 2018 · Heliyon
A Novel CAV1-MET Fusion in SCLC Transformation Responds to Crizotinib and Osimertinib Treatment
Jun Liu, Xin Li, Jun Peng · 2019 · Journal of Thoracic Oncology
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
A.S. Pal, Manvir Bains, Alejandra Agredo, Andrea L. Kasinski · 2020 · Biochemical Pharmacology
The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance
Vered Fuchs, Laila C. Roisman, Waleed Kian, Daniel Levin, Julia Dudnik, Hovav Nechushtan, Iris M. Goldstein, Addie Dvir, Lior Soussan‐Gutman, Roxana Grinberg et al. · 2021 · Lung Cancer
Retinoblastoma Protein Paralogs and Tumor Suppression
Mauricio Flores, David W. Goodrich · 2022 · Frontiers in Genetics
Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment
Julie A. Vendrell, Xavier Quantin, Isabelle Serre, Jérôme Solassol · 2020 · Therapeutic Advances in Medical Oncology
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
Elio Gregory Pizzutilo, Martino Pedrani, Alessio Amatu, Lorenzo Ruggieri, Calogero Lauricella, Silvio Marco Veronese, Diego Signorelli, Giulio Cerea, Laura Giuseppina Giannetta, Salvatore Siena et al. · 2021 · Cancers
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
Alvida Qvick, Bianca Stenmark, Jessica Carlsson, Johan Isaksson, Christina Karlsson, Gisela Helenius · 2021 · Molecular Medicine
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation
Àlvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redín, Fathema Z. Uddin, Swanand Rakhade, Vidushi Durani, Amin H. Sabet, Moniquetta Shafer, Wouter R. Karthaus, Samir Zaidi et al. · 2024 · Signal Transduction and Targeted Therapy
BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
Yihong Zhan, Yue Wang, Miao Qi, Panpan Liang, Yu Ma, Ting Li, Hui Li, Congmei Dai, Zhifeng An, Yitao Qi et al. · 2019 · Cell & Bioscience
Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy
Li Yu, Lyudmila A. Bazhenova, Kathryn Ann Gold, Lisa Tran, Van Hilburn, Peter Vu, Sandip Pravin Patel · 2022 · Translational Lung Cancer Research
Interleukin-17D promotes lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway
Zhenzhen Lin, Qiumin Huang, Junrong Liu, Hao Wang, Xuexi Zhang, Zhiyan Zhu, Wei Zhang, Yi‐Liang Wei, Zhe Liu, Wei Du · 2022 · Aging
Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers
Varadha Balaji Venkadakrishnan, Yasutaka Yamada, Kenny Weng, Osasenaga Idahor, Himisha Beltran · 2023 · Molecular Cancer Research
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib
Niamh Coleman, Andrew Charles Wotherspoon, Nadia Yousaf, Sanjay Popat · 2019 · Lung Cancer
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie P.L. Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo · 2025 · CA A Cancer Journal for Clinicians
PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion
Letian Zhang, Xiang Zhu, Congrong Liu, Bo Zhang, Jie Zheng, Prashant K. Singh, Wiam Bshara, Jianmin Wang, Eduardo Cortes Gomez, Xiaojing Zhang et al. · 2022 · Journal of Thoracic Oncology
In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition
Harun Patel, Rahul H. Pawara, Sanjay Javerilal Surana · 2018 · Computational Biology and Chemistry
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Nele Van Der Steen, Elisa Giovannetti, Daniela Carbone, Alessandro Leonetti, Christian Diego Rolfo, Godefridus J. Peters · 2018 · Cancer Drug Resistance
Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective
Michael Cabanero, Randeep S. Sangha, Brandon S. Sheffield, Mahadeo A. Sukhai, Mini Pakkal, Suzanne Kamel‐Reid, Aly Karsan, Diana N. Ionescu, Rosalyn Anne Juergens, Charles Andrew Butts et al. · 2017 · Current Oncology
Transformation or tumor heterogeneity: Mutations in EGFR , SOX2 , TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small‐cell lung cancer
Lidan Hao, Haiyang Chen, Lili Wang, Hanqiong Zhou, Zhe Zhang, Jing Han, Jiabao Hou, Yichen Zhu, He Zhang, Qiming Wang · 2023 · Thoracic Cancer
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Lee Jy, Richie Rashmin Bhandare, Sai H. S. Boddu, AFZAL BASHA SHAIK, Lakshmana Prabu Saktivel, Gaurav Gupta, Poonam Negi, Muna M. Barakat, Sachin Kumar Singh, Kamal Dua et al. · 2024 · Biomedicine & Pharmacotherapy
EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer
Cheng Yang, Shuxiang Ma, Jie Zhang, Yuchen Han, Li Wan, Wenlong Zhou, Xiaoyu Dong, Weiming Yang, Yu Chen, Lingyue Gao et al. · 2024 · Proceedings of the National Academy of Sciences
Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors
Xiaohua Shi, Huanli Duan, Xuguang Liu, Liangrui Zhou, Zhiyong Liang · 2016 · Oncotarget
Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
Xi Ding, Minxing Shi, Di Liu, Jingxue Cao, Kai-xuan Zhang, Rundong Zhang, Liping Zhang, Kaixing Ai, Bo Su, Jie Zhang · 2024 · Cell Communication and Signaling
Patterns in the tapestry of chromatin-bound RB
Ioannis Sanidas, Michael S. Lawrence, Nicholas J. Dyson · 2023 · Trends in Cell Biology
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
Nibal Saad, Aarati Poudel, Alina Basnet, Ajeet Gajra · 2017 · OncoTargets and Therapy
Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature
Bradford J. Siegele, Konstantin Shilo, Bo H. Chao, David Paul Carbone, Weiqiang Zhao, Olga B. Ioffe, Wilbur A. Franklin, Martin Joseph Edelman, Dara L. Aisner · 2016 · Lung Cancer
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study
Chiara Catania, Stephen V. Liu, Marina Chiara Garassino, A. Delmonte, Vieri Scotti, F. Cappuzzo, C. Genova, Alessandro Russo, Marco Russano, Chiara Bennati et al. · 2025 · ESMO Open
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer
Francesco Facchinetti, Claudia Proto, Roberta Minari, Marina Chiara Garassino, Marcello Tiseo · 2017 · Handbook of experimental pharmacology
Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
Zhengbo Song, Dongqing Lv, Shiqing Chen, Jianhui Huang, Liping Wang, Shuguang Xu, Huafei Chen, Guoqiang Wang, Quan D. Lin · 2021 · Frontiers in Oncology
Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective
Guoli Chen, Zhaohai Yang, James R. Eshleman, George Jabboure Netto, Ming‐Tseh Lin · 2016 · BioMed Research International
Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors
Yingxue Li, Yaoyao Chang, Jianfang Fu, Rongcai Ding, Lingyun Zhang, Tian Liang, Yajing Liu, Yue Liu, Jinxing Hu · 2021 · European Journal of Medicinal Chemistry
Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer
Adi F. Gazdar, John Dorrance Minna · 2016 · JNCI Journal of the National Cancer Institute
Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies
Brigida Stanzione, Alessandro Del Conte, Elisa Bertoli, Elisa De Carlo, Martina Bortolot, Sara Torresan, Michele Spina, Alessandra Bearz · 2025 · Cancers
NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
Hayato Koba, Hideharu Kimura, Taro Yoneda, Naohiko Ogawa, Kota Tanimura, Yuichi Tambo, Takashi Sone, Kazuyoshi Hosomichi, Atsushi Tajima, Kazuo Kasahara · 2021 · Translational Lung Cancer Research